Broncus Holding Corporation Logo

Broncus Holding Corporation

2216.HK

(1.0)
Stock Price

0,51 HKD

-11.09% ROA

-10.95% ROE

-1.85x PER

Market Cap.

49.507.694,71 HKD

1.27% DER

0% Yield

-271.35% NPM

Broncus Holding Corporation Stock Analysis

Broncus Holding Corporation Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Broncus Holding Corporation Fundamental Stock Analysis
# Analysis Rating
1 PBV

With a remarkably low PBV ratio (0.28x), the stock offers substantial upside potential at a bargain price.

2 DER

The stock has a minimal amount of debt (1%) relative to its ownership, showcasing a strong financial position and lower risk for investors.

3 ROE

Negative ROE (-12.3%) indicates poor financial performance, raising concerns about profitability and efficiency in utilizing shareholders' equity.

4 ROA

The stock's ROA (-12.98%) suggests that it's struggling to generate profits from its assets, making it a risky choice for investment.

5 Revenue Growth

Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.

6 Net Profit Growth

This company's net profit has remained flat over the past five years, suggesting a lack of growth and making it a less attractive investment opportunity.

7 Assets Growth

Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.

8 Graham Number

The Graham number analysis indicates that this company's stock price is likely overpriced, raising concerns about its investment potential.

9 Dividend Growth

The company's dividend growth has remained unchanged for three years, signaling a lack of positive momentum and making it a less favorable investment choice.

10 Dividend

Investors should note the absence of dividends from the company in the last three years, indicating potential financial challenges.

11 Buffet Intrinsic Value

Warren Buffett's formula suggests that the company's stock is overpriced (0), presenting a possible disadvantage for investors as its market price surpasses its estimated intrinsic value.

Broncus Holding Corporation Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Broncus Holding Corporation Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Sell
2 MACD Sell
3 RSI Hold
4 Stoch RSI Hold

Broncus Holding Corporation Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Broncus Holding Corporation Revenue
Year Revenue Growth
2019 8.072.000
2020 3.259.000 -147.68%
2021 10.891.000 70.08%
2022 9.413.000 -15.7%
2023 10.042.000 6.26%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Broncus Holding Corporation Research and Development Expenses
Year Research and Development Expenses Growth
2019 11.376.000
2020 9.353.000 -21.63%
2021 16.759.000 44.19%
2022 19.167.000 12.56%
2023 19.844.000 3.41%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Broncus Holding Corporation General and Administrative Expenses
Year General and Administrative Expenses Growth
2019 2.755.000
2020 4.024.000 31.54%
2021 18.546.000 78.3%
2022 9.229.000 -100.95%
2023 8.640.000 -6.82%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Broncus Holding Corporation EBITDA
Year EBITDA Growth
2019 -30.061.000
2020 -46.377.000 35.18%
2021 -233.844.000 80.17%
2022 -25.512.000 -816.6%
2023 -30.428.000 16.16%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Broncus Holding Corporation Gross Profit
Year Gross Profit Growth
2019 5.978.000
2020 2.506.000 -138.55%
2021 8.742.000 71.33%
2022 7.315.000 -19.51%
2023 6.402.000 -14.26%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Broncus Holding Corporation Net Profit
Year Net Profit Growth
2019 -32.551.000
2020 -48.786.000 33.28%
2021 -236.178.000 79.34%
2022 -28.036.000 -742.41%
2023 -26.720.000 -4.93%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Broncus Holding Corporation Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2019 0
2020 0 0%
2021 -1 0%
2022 0 0%
2023 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Broncus Holding Corporation Free Cashflow
Year Free Cashflow Growth
2019 -16.186.000
2020 -16.762.000 3.44%
2021 -33.375.000 49.78%
2022 -31.810.000 -4.92%
2023 -5.410.000 -487.99%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Broncus Holding Corporation Operating Cashflow
Year Operating Cashflow Growth
2019 -15.815.000
2020 -15.588.000 -1.46%
2021 -31.494.000 50.5%
2022 -30.954.000 -1.74%
2023 -5.108.000 -505.99%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Broncus Holding Corporation Capital Expenditure
Year Capital Expenditure Growth
2019 371.000
2020 1.174.000 68.4%
2021 1.881.000 37.59%
2022 856.000 -119.74%
2023 302.000 -183.44%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Broncus Holding Corporation Equity
Year Equity Growth
2019 -73.880.000
2020 -122.441.000 39.66%
2021 242.418.000 150.51%
2022 213.458.000 -13.57%
2023 185.370.000 -15.15%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Broncus Holding Corporation Assets
Year Assets Growth
2019 22.003.000
2020 39.877.000 44.82%
2021 252.806.000 84.23%
2022 221.942.000 -13.91%
2023 195.805.000 -13.35%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Broncus Holding Corporation Liabilities
Year Liabilities Growth
2019 95.883.000
2020 162.318.000 40.93%
2021 10.388.000 -1462.55%
2022 8.484.000 -22.44%
2023 10.435.000 18.7%

Broncus Holding Corporation Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0.02
Net Income per Share
-0.04
Price to Earning Ratio
-1.85x
Price To Sales Ratio
6.48x
POCF Ratio
-2.11
PFCF Ratio
-2.63
Price to Book Ratio
0.21
EV to Sales
-4.15
EV Over EBITDA
1.37
EV to Operating CashFlow
1.74
EV to FreeCashFlow
1.69
Earnings Yield
-0.54
FreeCashFlow Yield
-0.38
Market Cap
0,05 Bil.
Enterprise Value
-0,03 Bil.
Graham Number
0.6
Graham NetNet
0.32

Income Statement Metrics

Net Income per Share
-0.04
Income Quality
0.88
ROE
-0.11
Return On Assets
-0.11
Return On Capital Employed
-0.13
Net Income per EBT
1
EBT Per Ebit
0.84
Ebit per Revenue
-3.24
Effective Tax Rate
-0

Margins

Sales, General, & Administrative to Revenue
0.87
Research & Developement to Revenue
1.97
Stock Based Compensation to Revenue
0.04
Gross Profit Margin
0.68
Operating Profit Margin
-3.24
Pretax Profit Margin
-2.71
Net Profit Margin
-2.71

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-0.04
Free CashFlow per Share
-0.04
Capex to Operating CashFlow
-0.03
Capex to Revenue
0.08
Capex to Depreciation
0.3
Return on Invested Capital
-0.13
Return on Tangible Assets
-0.11
Days Sales Outstanding
477.16
Days Payables Outstanding
60.08
Days of Inventory on Hand
709.07
Receivables Turnover
0.76
Payables Turnover
6.08
Inventory Turnover
0.51
Capex per Share
0

Balance Sheet

Cash per Share
0,32
Book Value per Share
0,38
Tangible Book Value per Share
0.36
Shareholders Equity per Share
0.38
Interest Debt per Share
0
Debt to Equity
0.01
Debt to Assets
0.01
Net Debt to EBITDA
3.51
Current Ratio
18.85
Tangible Asset Value
0,18 Bil.
Net Current Asset Value
0,16 Bil.
Invested Capital
177019000
Working Capital
0,16 Bil.
Intangibles to Total Assets
0.05
Average Receivables
0,01 Bil.
Average Payables
0,00 Bil.
Average Inventory
4709000
Debt to Market Cap
0.05

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Broncus Holding Corporation Dividends
Year Dividends Growth

Broncus Holding Corporation Profile

About Broncus Holding Corporation

Broncus Holding Corporation, a medical device company, focuses on the development of interventional pulmonology products in Mainland China, the European Union, the United States, and internationally. The company provides navigation products, such as LungPoint Virtual Bronchoscopic Navigation, a computer-assisted image-based navigation software system; LungPoint Plus, a system that provides real-time navigation within the airways for lung biopsy and other procedures; and LungPro, a virtual bronchoscopic navigation product that provides three-dimensional real-time guided transbronchial needle aspiration and proprietary parenchymal navigation. It also offers treatment products comprising InterVapor, a targeted bronchoscopic thermal vapor ablation to ablate the diseased hyper-inflated lung segments; RF Generator + RF Ablation Catheter, a radiofrequency ablation system used in conjunction with a disposable lung radiofrequency ablation catheter, as well as radiofrequency ablation system that targets lung cancer; and H-Marker, a pulmonary surgical marker. In addition, the company provides treatment products, such as BioStarNeedle, a single use ultrasound-guided aspiration needle for retrieval of tissue samples; FleXNeedle, a multipurpose biopsy needle; Archimedes Sheath, a sterile single-use flexible tube that provides a working channel during a bronchoscopic procedure; Archimedes Dilation Balloon, a sterile single-use flexible tube with a balloon at or near the distal tip that is inserted through the bronchoscope or sheath and used to dilate the target lung tissue of the bronchial tree; and Steerable Sheath, a steerable sheath adjustment handle and a working channel. Broncus Holding Corporation was incorporated in 2012 and is headquartered in Hangzhou, China.

CEO
Mr. Hong Xu
Employee
208
Address
Room 801, Building 8
Hangzhou,

Broncus Holding Corporation Executives & BODs

Broncus Holding Corporation Executives & BODs
# Name Age
1 Ms. Elaine Lu
Director of Finance & Administration
70
2 Mr. Hong Xu
Chairman of the Board & Chief Executive Officer
70
3 Feng Yao
Senior Accountant
70
4 Thomas M. Keast
Vice President, Operation Director & Scientist in resident
70
5 Ms. Ka Yan Suen
Company Secretary
70

Broncus Holding Corporation Competitors